Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
0 competitors in Primary Immunodeficiency Diseases (PID)
View Full LandscapeTarget Indication
Primary Immunodeficiency Diseases (PID)
Clinical Trial
NCT05755035Last updated: 2/10/2026
No patent data available. Pre-approval drugs may not have Orange Book listings.
HyQvia
Replacement therapy in adults, children and adolescents (0-18 years) in: Primary immunodeficiency syndromes with impaired antibody production. Secondary immunodeficiencies (SID) in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure (PSAF)* or serum IgG level of < 4 g/L. *PSAF = failure to mount at least a 2-fold rise in IgG antibody titre to pneumococcal polysaccharide and polypeptide antigen vaccines. Immunomodulatory therapy in adults, children and adolescents (0 to 18 years) in: Chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy after stabilization with IVIg.
View on EMAHypertension
Type 2 Diabetes Mellitus
Primary Immunodeficiency Disease
Fabry Disease
Hypercholesterolemia